Pure Global: US AI Diagnostics & The FDA's New Data Mandate

The U.S. FDA has just redefined the rules for AI-powered medical software, shifting from one-time approvals to demanding continuous, real-world performance data. This new 'Lifecycle Assurance' approach signals a global trend towards total product lifecycle regulation, creating urgent challenges for MedTech innovators. This episode of MedTech Global Insights unpacks what this means for device manufacturers. We explore how this regulatory shift impacts market access, operational costs, and investment, forcing companies to move beyond passive complaint logging to a strategy of proactive, global data surveillance to maintain their place in the market. **Featured Case:** A successful German MedTech scale-up with FDA clearance for their AI stroke detection software is suddenly at risk. The new FDA mandate requires continuous performance data across diverse populations, a capability they never built. Their market access and next funding round are now in jeopardy. **Key Takeaways From This Episode:** * Why is the FDA suddenly focusing on 'Lifecycle Assurance' for AI/ML devices? * What specific real-world data are regulators now demanding post-approval? * How does the FDA's new stance align with regulatory trends in the EU and Asia? * Is your current post-market surveillance plan now obsolete? * What are the hidden infrastructure costs of maintaining compliance for SaMD? * How can a startup build a global compliance strategy from day one without breaking the bank? * What are the key differences between reactive and proactive surveillance? Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.